Clinical Trials Logo

Immune Thrombocytopenia clinical trials

View clinical trials related to Immune Thrombocytopenia.

Filter by:

NCT ID: NCT02834286 Recruiting - Clinical trials for Immune Thrombocytopenia

Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Start date: March 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab, eltrombopag and high-dose dexamethasone.

NCT ID: NCT02821572 Recruiting - Clinical trials for Immune Thrombocytopenia

Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)

PTI Fc
Start date: October 2, 2014
Phase:
Study type: Observational

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a peripheral destruction of platelets responsible for bleedings. Monocytes/macrophages play a double role by phagocyting platelets recognized by autoantibodies and by maintaining the autoimmune response via their antigen-presenting cell functions. Fcgamma receptors (FcγR), that are represented by activating receptors (FcγRI, FcγRIIa, FcγRIII) and an inhibiting one (FcγRIIb), are involved in the regulation of macrophages and have been reported to be dysregulated in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematous. The aim of this study is to compare the expression of FcγR in patients with ITP on circulating monocytes and on splenic macrophages.

NCT ID: NCT02298075 Recruiting - Clinical trials for Immune Thrombocytopenia

Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia

Start date: April 2016
Phase:
Study type: Observational

The primary objective of the study is the evaluation of sustained response rate after discontinuation of treatment with TPO-RAs, Eltrombopag and Romiplostim, in persistent or chronic pITP patients who failed one or more therapy lines, splenectomy included.

NCT ID: NCT02270801 Recruiting - Pregnancy Clinical Trials

Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy

Start date: October 2014
Phase: Phase 3
Study type: Interventional

This clinical trial is undertaking by Qilu Hospital of Shandong University, aims at evaluating efficacy and safety of rhTPO in management of ITP in pregnancy.

NCT ID: NCT01805648 Recruiting - Thrombocytopenia Clinical Trials

Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP

Start date: February 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of rhTPO in the maintenance treatment of ITP, to explore the appropriate dosing interval of the maintenance treatment of rhTPO .